Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

Join our team: Quality and Regulatory Analyst

Join our team: Quality and Regulatory Analyst
Created on 1/4/2019 4:51:11 PM

We're looking for a Quality and Regulatory Analyst to join our team. If you have what it takes, ple...
Join our team: Product Development Clinical Biochemist

Join our team: Product Development Clinical Biochemist
Created on 12/13/2018 4:34:15 PM

We're looking for a Product Development Clinical Biochemist to join our team. Find out more here